Volume 6, Issue 2 (May 2018)                   Res Mol Med (RMM) 2018, 6(2): 5-11 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Borumand N. Effect of UBE2Q on BECN and CEA Protein in Colorectal Cancer Cells. Res Mol Med (RMM) 2018; 6 (2) :5-11
URL: http://rmm.mazums.ac.ir/article-1-291-en.html
Department of Biotechnology, Faculty of Advanced Sciences and Technologies, University of Isfahan, Isfahan, Iran. , Nilufarborumand@gmail.com
Abstract:   (2758 Views)
Background: Expression of UBE2Q1, UBE2Q2, and members of the ubiquitin-conjugating enzyme family (E2) are affected in colorectal cancer (CRC). The BECN gene plays a key role in CRC cells. In gastrointestinal carcinoma therapy, tumor-associated antigens such as CEA are typically used.To investigate the association between UBE2Q1 and Beclin1 autophagy marker and CEA protein expression in LS180 CRC cell line.
Materials and methods: In this study, changes in the expression of BECN marker in LS180 cell lines with the vector containing UBE2Q1 were investigated using real-time PCR. The expression of CEA protein was also evaluated by western blotting. Statistical analyses were performed with Graph Pad Prism software.
Results: The results indicated reduced expression of BECN autophagy marker (P=0). Therefore, in the presence of UBE2Q1, cancer cells have less ability to induce autophagy. However, CEA protein levels in LS180 transfected cells with a UBE2Q1-ORF-containing plasmid decreased when compared to non-transfected cells.
Conclusion: The use of pharmacologic inhibitors related to the autophagy mechanism can be a novel approach in cancer therapy.  
Full-Text [PDF 1392 kb]   (1189 Downloads)    
Type of Study: Research | Subject: Genetic
Published: 2018/05/15

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | Research in Molecular Medicine

Designed & Developed by : Yektaweb